1. Pink Sheet
  2. >>Geography
  3. >>Europe

Experts Look At How To Speed Approval Of Variant COVID-19 Vaccines

‘Global Forum’ Needed For Consensus On Requirements

 
• By Ian Schofield

Senior members of three key regulatory and health bodies this week gave their assessments of the protection that existing COVID-19 vaccines may offer against future strains of the virus, and the requirements for developing and assessing modified vaccines.

Concept image related to the concern that SARS-CoV-2 variants from UK, Brazil and South Africa might undermine available vaccines
Coronavirus variants have emerged in several countries • Source: Shutterstock

Companies seeking marketing approval of vaccines against variants of the SARS-CoV-2 virus will need to provide solid justification for the choice of variants they intend to include in their vaccines, based on a good understanding of the strains circulating at the time the variant is selected.

Regulators are discussing how new versions of existing COVID-19 vaccines can be rapidly approved, and the European Commission is close...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

US Tariffs And The EU’s Critical Medicines Act: Lessons On Nearshoring And CMO Diversification

 
• By Francesca Bruce

Nearshoring production and diversifying contract manufacturing networks can help companies stave off cost increases that will be reflected in higher medicine prices.

EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU

 
• By Vibha Sharma

Eli Lilly and PharmaMar were set to make their case before the European Medicines Agency this week as part of re-examination procedures for their respective drugs Kisunla and Aplidin.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By Vibha Sharma

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

More from Geography

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Leqembi Facing 15% Price Cut In Japan

 
• By Lisa Takagi

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.